Posts

OneDayAdvisor Master Guide: Investing, AI, Technology & Health

By -
Image
OneDayAdvisor Master Guide & Site Index OneDayAdvisor is a research and decision platform covering money, investing, artificial intelligence, technology, healthcare and consumer decision-making. This master guide connects the site's major research areas, tools and practical guides in one place. Last updated:  October 2026  |  Purpose: Master pillar + site index Start here. OneDayAdvisor is designed around a simple idea: better decisions begin with better information. Instead of treating every topic as an isolated article, this site organizes research around the decision a reader is trying to make, the evidence needed to evaluate it, the risks involved and the tools available to help. On this page What Is OneDayAdvisor? Start Here: Choose Your Decision The OneDayAdvisor Knowledge Architecture Money & Investing ...
Post a Comment
Read more

Top Cancer Drug Companies (2026 Update): Leaders by Revenue, Pipeline, and Growth

By -
Image
Medically & Financially Reviewed by: Dr. Frank Yap, MD, MBA | Written by: OneDayAdvisor Editorial Team | Last Updated: September 2026 Quick Answer Merck & Co. remains the world's top cancer drug company by 2025 oncology revenue (~$35.4 billion, driven overwhelmingly by Keytruda) , followed by Roche (~$29–30 billion), AstraZeneca ($25.6 billion), Johnson & Johnson ($25.4 billion), and Bristol Myers Squibb (~$25.0 billion). Global oncology drug spending topped an estimated $291 billion in 2025 and is projected to reach roughly $467 billion by 2030 (IQVIA Institute), making cancer treatment the single largest therapeutic category in pharmaceuticals. The competitive picture keeps shifting: Merck's Keytruda faces a 2028 patent cliff, BMS's Revlimid has already lost roughly half its sales to generics, and a wave of Chinese-originated antibody-drug conjugat...
Post a Comment
Read more

China’s Draft Ban on Foreign Acquisitions of Biopharma Platforms: What It Means for Licensing Deals

By -
Image
Biotech Deals · Updated October 2026 · In this article Quick answer What China actually proposed What is not covered: licensing Why Beijing is doing this Table: 23 largest China licensing deals What the table shows Implications for dealmakers and investors The US side of the equation What to watch next Source quality and evidence grading FAQ AI personalization guide Sources Quick answer Bottom line: On October 16, 2026, China published a draft update to its export blacklist that would ban foreign acquisitions of proprietary cell and gene therapy, siRNA and pathogen gain-of-function platforms , and require approval for full transfers of related target-discovery technologies. Out-licensing...
Post a Comment
Read more